Overview
FAQs
Research Feed
Update History
References2026-07-05
Page created majorIntervention page: ginsenoside pharmacology and gut-microbiota interaction, Conditions table (MS-related fatigue), clinical evidence, FAQs, and Research Feed.
Did you know?
Ginseng and the gut are a two-way street: gut bacteria convert ginseng's ginsenosides into their most active forms, while ginseng in turn reshapes the gut microbiota. In a controlled trial it eased one of multiple sclerosis's most stubborn symptoms, fatigue.
Panax Ginseng
Panax ginseng is a medicinal root whose ginsenosides have adaptogenic, anti-inflammatory, and antifatigue properties, and which is metabolized by and reshapes the gut microbiota.
Page Snapshot
Microbiome-targeted interventions (MBTIs) are validated using a dual-evidence logical framework. First, the intervention must realign the condition’s microbiome signature by increasing beneficial taxa that are consistently depleted and reducing pathogenic taxa that are consistently enriched. Second, the intervention must demonstrate measurable clinical benefit. Concordance of these effects in the same context validates the intervention as an MBTI and supports the clinical relevance of the microbiome signature.
Karen Pendergrass
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreOverview
Panax ginseng is a perennial herb whose root has been used in traditional medicine for centuries. Its active constituents are ginsenosides, triterpenoid saponins with adaptogenic, anti-inflammatory, and antifatigue properties. Ginseng is relevant to microbiome-targeted therapy in both directions: gut bacteria metabolize ginsenosides into their most active forms, and ginseng intake in turn reshapes gut microbial composition. It has been studied for fatigue, immune support, and metabolic health.
Mechanism of Action
Ginsenosides exert anti-inflammatory and antioxidant effects and modulate immune-cell activity. They are biotransformed by gut bacteria into more bioactive metabolites, so an individual's microbiome shapes the response, while ginseng reciprocally alters that microbiome. Its antifatigue action is linked to effects on the hypothalamic-pituitary-adrenal stress axis and on cellular energy metabolism.
Conditions
Panax ginseng has been evaluated across fatigue and immune-related complaints. Its controlled evidence in a neurological disease is in multiple sclerosis, for the symptom of fatigue.
| Condition | Findings | MBTI Status |
|---|---|---|
| Multiple Sclerosis | A randomized, double-blind, placebo-controlled pilot (n=60) found 250 mg ginseng twice daily for three months improved fatigue (Modified Fatigue Impact Scale) and quality of life (MSQOL-54) versus placebo, with good tolerance.[1] | Promising Candidate |
In that pilot, of 60 randomized patients 52 completed, and ginseng outperformed placebo on fatigue (p = 0.046) and quality of life (p less than or equal to 0.0001), at 250 mg twice daily for three months with no serious adverse events.[1] Ginseng can interact with anticoagulants, antidiabetic drugs, and stimulants, and is generally avoided in pregnancy; its evidence in other conditions remains largely preclinical.
FAQs
What is Panax Ginseng?
Quick answer: Panax ginseng is a perennial herb whose root has been used in traditional medicine for centuries. Its active constituents are ginsenosides, triterpenoid saponins with adaptogenic, anti-inflammatory, and antifatigue properties. Ginseng is relevant to microbiome-targeted therapy in both directions: gut bacteria metabolize ginsenosides into their most active forms, and ginseng intake in turn reshapes gut microbial composition. It has been studied for fatigue, immune support, and metabolic health.
How does Panax Ginseng work?
Quick answer: Ginsenosides exert anti-inflammatory and antioxidant effects and modulate immune-cell activity. They are biotransformed by gut bacteria into more bioactive metabolites, so an individual's microbiome shapes the response, while ginseng reciprocally alters that microbiome. Its antifatigue action is linked to effects on the hypothalamic-pituitary-adrenal stress axis and on cellular energy metabolism.
What conditions can Panax Ginseng help?
Quick answer: Panax ginseng has been evaluated across fatigue and immune-related complaints. Its controlled evidence in a neurological disease is in multiple sclerosis , for the symptom of fatigue.
Research Feed
Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study
2013
A randomized pilot found Panax ginseng improved MS-related fatigue and quality of life over three months.
What was studied?
The efficacy and safety of Panax ginseng for fatigue and quality of life in multiple sclerosis.
Who was studied?
Sixty female MS patients randomized double-blind to 250 mg ginseng or placebo twice daily for three months; 52 (86 percent) completed the trial.
What were the key findings?
Ginseng improved fatigue on the Modified Fatigue Impact Scale (p = 0.046) and quality of life on the MSQOL-54 (p less than or equal to 0.0001) versus placebo, with good tolerance and no serious adverse events.
What are the implications?
Ginseng is a promising, well-tolerated candidate for relieving MS-related fatigue, though larger confirmatory trials are needed.
Update History
References
- Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study. Etemadifar M, Sayahi F, Abtahi SH, et al. (Int J Neurosci. 2013)
Reference [1]
Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study.
Etemadifar M, Sayahi F, Abtahi SH, et al. Int J Neurosci. 2013
View source